RxDoctor Payments Data

Andrew Dublin, MD

Interventional Cardiology · Walnut Creek, CANPI 1215085246

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $40,160 of the $59,242 with a category attached, or 67.8%. 50 manufacturers reported payments, led by Johnson & Johnson at 31.4% of the total. Reporting peaked in 2021 at $20,726 and has fallen 89.1% since, to $2,255 in 2025.

$59,242in general payments, 2019–2025

Across 690 payments — averaging $85.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$19K
  • AstraZeneca$17K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Cathworks, Inc.$3K
  • Boston Scientific$1K
  • Abbott$1K
  • plus $10K from 44 others
$384,510in research payments, 2019–2025

Across 69 payments — averaging $5572.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$263K
  • Procyrion, Inc.$64K
  • CSL Behring$58K

What the payments were for

  • Consulting fees$2,8005%
  • Speaking & faculty fees$40,16068%
  • Travel & lodging$2690%
  • Food & beverage$15,82527%
  • Education$1880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,242 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$598,296
Medicare patients
2,069
Services billed
7,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$524,035
XareltoRivaroxaban159$230,688
Repatha SureclickEvolocumab164$213,737
MultaqDronedarone Hcl88$166,428
FarxigaDapagliflozin Propanediol139$149,977
EntrestoSacubitril/Valsartan98$131,048
JardianceEmpagliflozin78$98,343
Praluent PenAlirocumab46$55,338
OzempicSemaglutide34$40,619
BrilintaTicagrelor17$18,376
Droxidopa11$17,427
Repatha SyringeEvolocumab11$15,683
Atorvastatin Calcium852$9,267
Metoprolol Succinate471$8,819
Ezetimibe237$8,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$494$524,035391 claims
Johnson & JohnsonXarelto$18,581$230,688159 claims
AstraZenecaFarxiga, Brilinta$17,119$168,354156 claims
Sanofi-aventis U.S. LLCMultaq$250$166,42888 claims
NovartisEntresto$594$131,04898 claims
Boehringer IngelheimJardiance$646$98,34378 claims
Novo NordiskOzempic$151$40,61934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →